ReviewArteriosclerosis, thrombosis, and vascular biology2020
COVID-19 and the Heart and Vasculature: Novel Approaches to Reduce Virus-Induced Inflammation in Patients With Cardiovascular Disease.
Review in Arteriosclerosis, thrombosis, and vascular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 33 citations in OpenAlex.
- Sustained Vascular Inflammatory Effects of SARS-CoV-2 Spike Protein on Human Endothelial Cells.Inflammation · 2025Article
- A Review: Can Cytokines Induce Vascular Inflammation as a Sequela of Viral Infections?Health science reports · 2025Article
- Elevated Levels of IL-1Ra, IL-1β, and Oxidative Stress in COVID-19: Implications for Inflammatory Pathogenesis.Journal of clinical medicine · 2025Article
- Biomarkers of glucose homeostasis as mediators of the relationship of body mass index and waist circumference with COVID-19 outcomes among postmenopausal women: The Women's Health Initiative.Clinical nutrition (Edinburgh, Scotland) · 2023Article
- An observational study on factors associated with ICU mortality in Covid-19 patients and critical review of the literature.Scientific reports · 2023Review
- Major adverse cardiovascular events are associated with necroptosis during severe COVID-19.Critical care (London, England) · 2023Observational
- Necroptosis Drives Major Adverse Cardiovascular Events During Severe COVID-19.Research square · 2023Article
- Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology.Frontiers in immunology · 2023Review
- Pathomechanisms of SARS-CoV-2 infection and development of atherosclerosis in patients with COVID-19: A review.Medicine · 2022Review
- Atherosclerosis by Virus Infection-A Short Review.Biomedicines · 2022Review
- COVID-19 Pandemic Impact on Trajectories in Cardiometabolic Health, Physical Activity, and Functioning Among Adults from the 2006-2020 Health and Retirement Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Socio-demographic, lifestyle and health characteristics as predictors of self-reported Covid-19 history among older adults: 2006-2020 Health and Retirement Study.American journal of infection control · 2022Article
- Predictors of Covid-19 level of concern among older adults from the health and retirement study.Scientific reports · 2022Article
- COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences.Frontiers in cell and developmental biology · 2022Review
- Inflammasomes as Potential Therapeutic Targets in Atherosclerotic Cardiovascular Disease.Endocrine, metabolic & immune disorders drug targets · 2022Review
- Sulodexide Significantly Improves Endothelial Dysfunction and Alleviates Chest Pain and Palpitations in Patients With Long-COVID-19: Insights From TUN-EndCOV Study.Frontiers in cardiovascular medicine · 2022Article
- COVID-19-induced cardiovascular damage differs from other prevalent viruses.Cardiology plus · 2021Review
- Unraveling the molecular crosstalk between Atherosclerosis and COVID-19 comorbidity.Computers in biology and medicine · 2021Article
- Review
- The Mechanisms of the Development of Atherosclerosis in Prediabetes.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented challenge and opportunity for translational investigators to rapidly develop safe and effective therapeutic interventions. Greater risk of severe disease in COVID-19 patients with comorbid diabetes mellitus, obesity, and heart disease may be attributable to synergistic activation of vascular inflammation pathways associated with both COVID-19 and cardiometabolic disease. This mechanistic link provides a scientific framework for translational studies of drugs developed for treatment of cardiometabolic disease as novel therapeutic interventions to mitigate inflammation and improve outcomes in patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.